AEON Biopharma
AEON
AEON
71 hedge funds and large institutions have $202M invested in AEON Biopharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$9.78M |
| 2 |
SC
Sculptor Capital
New York
|
+$4.69M |
| 3 |
SCM
Saba Capital Management
New York
|
+$4.23M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.48M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.35M |
Top Sellers
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$4.99M |
| 2 |
Blackstone Inc
New York
|
-$4.5M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.76M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.06M |
| 5 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$1.84M |
